Get the Stockscreener App
4.265
0.35%
0.015
After Hours:
4.27
0.005
+0.12%
Coya Therapeutics Inc stock is traded at $4.265, with a volume of 81,169.
It is up +0.35% in the last 24 hours and down -22.45% over the past month.
Coya Therapeutics Inc is a clinical-stage biotechnology company focused on developing proprietary new therapies to enhance the function of regulatory T cells (Tregs). The company's initial development programs are focused on neurodegenerative, chronic inflammatory, autoimmune, and metabolic diseases with high unmet medical needs.
See More
Previous Close:
$4.25
Open:
$4.33
24h Volume:
81,169
Relative Volume:
0.41
Market Cap:
$100.04M
Revenue:
$7.94M
Net Income/Loss:
$-21.13M
P/E Ratio:
-3.9425
EPS:
-1.0818
Net Cash Flow:
$-16.17M
1W Performance:
-3.94%
1M Performance:
-22.45%
6M Performance:
-11.88%
1Y Performance:
-36.06%
1-Day Range:
$4.24
$4.405
1-Week Range:
$4.21
$4.5887
52-Week Range:
$3.7101
$7.75
Coya Therapeutics Inc Stock (COYA) Company Profile
Name
Coya Therapeutics Inc
Sector
Industry
Phone
650.739.3939
Address
12645 MEMORIAL DR., SUITE F1 #305, HOUSTON
Compare COYA vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
COYA
Coya Therapeutics Inc
|
4.265 | 99.69M | 7.94M | -21.13M | -16.17M | -1.0818 |
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Coya Therapeutics Inc Stock (COYA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-09-25 | Initiated | Lake Street | Buy |
| Dec-04-24 | Initiated | D. Boral Capital | Buy |
Coya Therapeutics Inc Stock (COYA) Latest News
Coya Therapeutics (NASDAQ: COYA) holder discloses 3.3% stake in amended filing - Stock Titan
Coya Therapeutics Inc (COYA) Balance Sheet - TradingKey
Coya Therapeutics Inc (COYA) Cash Flow - TradingKey
COYA|Coya Therapeutics Inc|Price:4.250|Chg%:-0.130 - TradingKey
Coya Therapeutics Inc (COYA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Coya Therapeutics Inc (COYA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Coya Therapeutics Inc (COYA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Coya Therapeutics Market Sentiment - Benzinga España
Coya Therapeutics Inc (COYA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Coya Therapeutics Inc (COYA) Income Statement - TradingKey
Coya Therapeutics, Inc. Revenue Breakdown – NASDAQ:COYA - TradingView
Coya Therapeutics Inc (COYA) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Discipline and Rules-Based Execution in COYA Response - Stock Traders Daily
Price to book forward of Coya Therapeutics, Inc. – NASDAQ:COYA - TradingView
Price to earnings forward of Coya Therapeutics, Inc. – NASDAQ:COYA - TradingView
Price to sales forward of Coya Therapeutics, Inc. – NASDAQ:COYA - TradingView
Coya Therapeutics (COYA) Dips 1.3% as Stock Tests Key Support LevelsBear Pennant - dars.gov.et
Coya Targets ALS Trial Readout in Q1 2027, H.C. Wainwright Sets US$18 Price Target - Streetwise Reports
Houston ALS Biotech Coya Eyes 2028 Approval Path - Streetwise Reports
Coya Therapeutics(COYA) Stock Options Chain | Quotes & News - Moomoo
Coya Therapeutics (COYA) Slips 1.87% as Stock Tests Key Support Near $5.00Triple Top - dars.gov.et
Coya Therapeutics to Host Virtual Webinar on the Intersection of Repetitive Head Trauma, Brain Inflammation and Neurodegenerative Disease - AOL.com
COYA Q1 2026 Earnings: Narrower-Than-Expected Loss as Pipeline AdvancesProfitability Analysis - dars.gov.et
Roth MKM Maintains Coya Therapeutics(COYA.US) With Buy Rating, Maintains Target Price $12 - Moomoo
Coya Therapeutics Dips 2.3% as Stock Tests Key Support at $5.42Max Pain Level - dars.gov.et
Is Coya Therapeutics, Inc. (COYA) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
Behavioral Patterns of COYA and Institutional Flows - Stock Traders Daily
Coya Therapeutics, Inc. Actuals & Estimates (NASDAQ:COYA) - TradingView
Coya Therapeutics, Inc. Actuals & Estimates (BOATS:COYA) - TradingView
Coya Therapeutics Price Target Maintained With a $14.00/Share by Chardan Capital - Moomoo
H.C. Wainwright Remains a Buy on Coya Therapeutics, Inc. (COYA) - The Globe and Mail
Coya Therapeutics, Inc. Reports 2026 Annual Meeting Results and Company Information (NASDAQ: COYA) - Minichart
Coya Therapeutics Shareholders Back Board, Auditor at Meeting - TipRanks
Coya Therapeutics (NASDAQ: COYA) shareholders back board nominees and 2026 auditor - Stock Titan
COYA Forecast — Price Target — Prediction for 2027 - TradingView
H.C. Wainwright Maintains Coya Therapeutics(COYA.US) With Buy Rating, Maintains Target Price $18 - Moomoo
Coya Therapeutics (COYA) Investor update Summary - Quartr
COYA Q1 2026 Earnings: Narrower-than-Expected Loss Drives Positive SentimentEarnings Recovery Stocks - dars.gov.et
Number of shareholders of Coya Therapeutics, Inc. – NASDAQ:COYA - TradingView
COYA Therapeutics Inc. (COYA) Edges Higher as Stock Hovers Near ResistanceRip Sell Trade - dars.gov.et
Exosomes Pipeline 2026: Therapies Under Investigation, Clinical Trials Milestones, and FDA Approvals by DelveInsight | Innovex Therapeutics, Coya Therapeutics, EV Therapeutics, Endosome Therapy StemXO - Barchart.com
COYA Technical Analysis & Stock Price Forecast - Intellectia AI
COYA Q1 2026 Earnings: Wider-Than-Expected Loss Still Beats Estimates as Biotech Advances PipelineNext Quarter Guidance - dars.gov.et
Coya Therapeutics to Present ALSTARS Trial Design at the ENCALS 2026 Meeting - BioSpace
Coya Therapeutics Inc (COYA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Coya Therapeutics Inc (COYA) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Coya Therapeutics Inc (COYA) Institutional Confidence - TradingKey
Coya Therapeutics Inc (COYA) Valuation: PE, PB & Fair Value Analysis - TradingKey
COYA Maintains Buy Rating by Chardan Capital -- Price Target at $14 - GuruFocus
Coya Therapeutics (COYA) Gains 2.16% as Stock Nears Key Resistance ZoneDip Buy Trade - newsline.com
Oruka Therapeutics, Inc. (ORKA) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance
Coya Therapeutics Inc Stock (COYA) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.97%
0.83%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):